Skip to product information

ASN Kidney Week 2024 – Onconephrology Cancer, Its Treatments, and the Kidneys

ASN Kidney Week 2024 – Onconephrology Cancer, Its Treatments, and the Kidneys

Regular price $120.00 USD
Regular price $120.00 USD Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
ASN Kidney Week 2024 – Onconephrology Cancer, Its Treatments, and the Kidneys

ASN Kidney Week 2024 – Onconephrology Cancer, Its Treatments, and the Kidneys

Regular price $120.00
Regular price $120.00 Sale price
SAVE Liquid error (snippets/price line 116): Computation results in '-Infinity'% Sold out
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
  • Share positive thoughts and feedback from your customer.

    Author
    View full details

    Kidney Week 2024: Early Programs

    Each Early Program addresses a specific topic in nephrology and requires separate registration from the Annual Meeting.


     

    Onconephrology: Cancer, Its Treatments, and the Kidneys

    Course Description


    Cancer is one of the leading causes of death worldwide. Patients with cancer who have kidney-related issues have a worse prognosis and higher morbidity and mortality. Onconephrology is a field dedicated to understanding and treating the complex kidney problems that arise in patients with cancer. This program focuses on how cancer and its treatments affect the kidneys. Lectures and case-based discussions enable participants to refine their knowledge of AKI, hypertension, and electrolyte abnormalities resulting from novel and longstanding cancer treatments; consider the impact of kidney diseases in special populations with cancer (e.g., in patients with ESKD and kidney transplantation); and learn about hematologic conditions and their effects on the kidneys.

    Course Objective(s)

    Upon completion of this program, the participant will be able to: 1) identify clinical and laboratory features of kidney-related toxicities across a spectrum of cancer therapies; 2) discuss management of patients diagnosed with cancer who have coexistent AKI, CKD, and/or kidney transplants; and 3) describe kidney and electrolyte disorders associated with hematologic conditions and best practices for clinical management.

     

    Topics

     

    : See here